Germany cuts GKV reimbursement for medical cannabis flower

What changed

The Bundestag passed the GKV-Beitragssatzstabilisierungsgesetz, a broad statutory health insurance savings package, on 10 July 2026. Inside it, an amendment to Social Code Book V section 31(6) removes flowers from the list of cannabis forms the GKV must reimburse for seriously ill patients.

Extracts, dronabinol and nabilone remain in the framework, but access got harder. Before an extract claim is valid under GKV, the treating physician must first prescribe an approved cannabis-containing finished medicine for a six-month therapeutic trial. Only after that trial (or a narrow statutory bypass) can extract reimbursement proceed.

That six-month gateway was not in the cabinet draft. It appeared in a coalition amendment in the health committee (BT-Drucksache 21/7016, 8 July) and was voted into the final package two days later. There is no transition arrangement for patients already on stable flower treatment.

What it means for buyers

• Retail CBD oils and cosmetics: Not covered by this GKV clause. German OTC CBD still sits under the usual BtMG THC limit (0.3% total THC) and EU Novel Food rules for ingestibles.
• Medical flower patients: Statutory reimbursement for flower ends under the new text. Clinics and pharmacies will shift scripts toward extracts or finished medicines where GKV cover is sought.
• Extract patients: Expect a finished-medicine trial step before extract reimbursement, even when chronic pain was the main indication in BfArM survey data (about 76% of GKV cannabis patients).
• Do not confuse headlines: “Germany bans cannabis flower” in this story means GKV reimbursement, not a nationwide ban on all hemp flower retail.

Why industry objected

Pharmacy and industry groups argued the savings package may raise costs: compounded extracts can be cheaper than finished medicines, and most patients’ conditions do not match the four authorised finished products’ labels. The Bundesverband Cannabis Wirtschaft (BvCW) said GKV cannabis spend was about EUR 205 million in 2025 against a much larger structural GKV funding gap, making flower a thin savings line with high patient disruption.

Context for EU CBD shoppers

Germany still sells low-THC CBD oils and cosmetics under the retail rules described in our Germany guide. Medical cannabis reimbursement is a separate channel. France’s Novel Food edible crackdown and Italy’s Article 18 flower fights are different problems again – product format and legal channel still decide risk more than a single Europe-wide headline.

Sources

• Business of Cannabis (10 Jul 2026) – Germany GKV flower ban and extract trial rule

Related guides

• Is CBD legal in Germany? (2026 country guide)
• Best CBD oils in Europe 2026 – lab-checked comparison

FAQ

Did Germany ban CBD flower for everyone in July 2026?

No. The 10 July vote removes medical cannabis flower from statutory health insurance (GKV) reimbursement. It is not the same as a blanket ban on all retail hemp or CBD flower.

Can I still buy CBD oil online in Germany after this vote?

Yes under the usual retail rules: EU-certified hemp, 0.3% total THC or lower, and Novel Food uncertainty for ingestibles. The GKV change targets reimbursed medical cannabis, not drugstore CBD oils.

What is the new rule for medical cannabis extracts?

Before GKV extract reimbursement, doctors must generally run a six-month trial of an approved cannabis finished medicine first, unless a narrow statutory bypass applies.